Palantir’s New Healthcare Deal Boosts AI and Data Reach

Palantir Technologies (PLTR) has partnered with OneMedNet Corp. (ONMD) to integrate its Artificial Intelligence Platform (AIP) into OneMedNet's iRWD, enhancing healthcare AI and data analytics by leveraging real-world imaging data for clinical research. This multi-year agreement significantly expands Palantir's footprint in the regulated healthcare sector, reinforcing its commercial growth strategy, which saw 93% year-over-year U.S. commercial revenue growth and a projected $1.302 billion in U.S. commercial revenue. The partnership underscores Palantir's strategic diversification beyond government contracts and contributes to its robust stock performance, attracting bullish options activity ahead of its upcoming earnings report, despite some analyst price targets suggesting a premium valuation.

Analysis

Palantir Technologies (PLTR) partnered with OneMedNet (ONMD), integrating its AIP to enhance healthcare AI and data analytics. This multi-year agreement leverages OneMedNet's five billion claims and 131 million clinical exams, strengthening Palantir's regulated healthcare footprint and data credibility.

This collaboration highlights Palantir's commercial diversification, with U.S. commercial revenue growing 93% year-over-year and customer count increasing 64% last quarter. The company projects U.S. commercial revenue to exceed $1.302 billion (over 85% growth), with commercial operations now contributing 44% of total revenue.

Despite a $141.28 consensus analyst price target (20% downside from Oct. 14), PLTR stock is up over 137% in 2025 (YTD) and 20% in three months. The stock consolidates ahead of its November 3rd earnings report, a key catalyst, with bullish options activity suggesting upside.

However, a 10% increase in short interest over the past month presents a risk. An earnings miss could trigger selling pressure, suggesting a potentially stretched valuation.

Key Decisions for Investors

• Monitor Palantir's Q3 earnings report on November 3rd closely, as strong commercial growth and positive guidance are essential to sustain current momentum and justify its premium valuation.
• Evaluate the impact of the OneMedNet partnership on Palantir's healthcare segment revenue and future commercial pipeline, as this diversification is key to long-term growth beyond government contracts.
• Consider the elevated short interest and analyst price targets, which suggest potential downside risk if earnings fail to meet high expectations, despite bullish options activity.